On Wednesday, Shares of Apple Inc. (NASDAQ:AAPL), gained 1.15% to $128.88.
Apple, previewed watchOS™ 2, the first major software update for Apple Watch™, giving developers the tools to build faster and more powerful apps running natively on Apple Watch. Starting recently, developers can take advantage of innovative hardware features of Apple Watch counting the Digital Crown™, Taptic Engine™ and heart rate sensor, together with software APIs to build new app experiences. Accessible to Apple Watch users this fall, watchOS 2 also comprises new watch faces, third-party app information as watch face complications and new communication capabilities in Mail, Friends and Digital Touch.
“We are thrilled with the feedback we’re getting from Apple Watch customers, and after just a few weeks of availability we’re excited for developers to start building native apps for watchOS 2,” said Kevin Lynch, Apple’s vice president of Technology. “We think Apple Watch users will love being able to see information from their favorite apps right on the watch face, and enjoy the many new experiences developers will dream up now that they have access to even more innovative features of Apple Watch.”
Apple Inc. designs, manufactures, and markets mobile communication and media devices, personal computers, watches, and portable digital music players worldwide. The company also sells related software, services, accessories, networking solutions, and third-party digital content and applications.
Shares of Halliburton Company (NYSE:HAL), gained 2.12% to $46.24, during its last trading session, as U.S. oil prices rose to a new 2015 high Wednesday after U.S. data showed stronger-than-predictable demand for crude oil and gasoline.
Light, sweet crude for July delivery settled up $1.29, or 2.1%, at $61.43 a barrel on the New York Mercantile Exchange, the highest settlement since Dec. 9. Brent, the global benchmark, rose 82 cents, or 1.3%, to $65.70 a barrel on ICE Futures Europe, according to WSJ.
Halliburton Company provides a range of services and products to the upstream oil and natural gas industry worldwide. The company operates through two segments, Completion and Production, and Drilling and Evaluation.
Finally, Heron Therapeutics, Inc. (NASDAQ:HRTX), ended its last trade with 10.66% gain, and closed at $28.86, hitting its highest level.
Heron Therapeutics, declared the pricing of an underwritten offering of 4,800,000 shares of its common stock, offered at a price of $24.75 per share. Heron Therapeutics, Inc. has granted the underwriters a 30-day option to purchase up to an additional 720,000 shares of common stock. The offering is predictable to close on or about June 15, 2015, subject to customary closing conditions. Jefferies LLC, Leerink Partners LLC and Cowen and Company, LLC are acting as joint book-runners for the offering. JMP Securities LLC, Brean Capital, LLC and Noble Life Science Partners are acting as co-managers for the offering.
The gross offering size will be about $119 million before deducting customary underwriting discounts and commissions and offering expenses. Heron Therapeutics, Inc. intends to use the net proceeds from the underwritten offering primarily for general corporate purposes, which comprise, but are not limited to, the commercial launch of SUSTOL® (granisetron injection, extended release), if approved, funding the company’s ongoing and future clinical trials, preclinical development work, and for general and administrative expenses, or other product development activities.
Heron Therapeutics, Inc., a biotechnology company, develops products to address unmet medical needs using its proprietary Biochronomer polymer-based drug delivery platform in the United States. Its drug delivery platform is designed to enhance the therapeutic profile of injectable pharmaceuticals.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
